Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease

NCT05766813 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson Disease

Interventions

DRUG: Lenrispodun
DRUG: Placebo

Sponsor

Intra-Cellular Therapies, Inc.